Last updated: February 27, 2026
What is the Product?
NDC 69918-0515 is a biosimilar version of a branded biologic drug. This specific NDC corresponds to Nivolumab (Opdivo) biosimilar, indicated for cancers such as melanoma, non-small cell lung cancer, and others. The biosimilar aims to compete with the innovator product, offering similar efficacy at a lower price point.
Market Landscape
Size and Growth Trajectory
- The global oncology biosimilar market is projected to reach approximately $10 billion by 2027.
- The U.S. represents roughly 50% of the market, driven by high cancer prevalence and reimbursement policies favoring biosimilars.
- The adoption rate for biosimilars in oncology has increased from 8% in 2018 to approximately 30% in 2022.
Key Competitors
| Product Name |
Manufacturer |
Indication(s) |
Launch Date |
Pricing Strategy |
| Nivolumab (Opdivo) |
Bristol-Myers Squibb |
Melanoma, lung, renal, others |
2014 |
Premium, high price |
| Nivolumab Biosimilar 1 |
Celltrion |
Similar indications |
2021 |
15-25% discount initial |
| Nivolumab Biosimilar 2 |
Samsung Bioepis |
Similar indications |
2022 |
Competitive pricing |
Pricing Dynamics
- The innovator drug's list price is approximately $150,000 per year.
- Biosimilar prices typically range from 20-30% below the originator.
- Early market prices for NDC 69918-0515 are projected between $112,500 and $120,000 per year, depending on negotiated discounts and payer arrangements.
Price Projections
Short-Term (1-2 Years)
- Entry price is expected around $112,500, reflecting a 25% discount on the originator.
- Price reductions of 5-10% are expected as market penetration increases and more biosimilars enter the market.
- Payer negotiations and formulary placements will influence final net prices.
Mid to Long-Term (3-5 Years)
- Prices are projected to decline further, reaching $100,000-$110,000 per year.
- Increased competition and patent expiry of other biologics will accelerate price erosion.
- The biosimilar could capture up to 40% of the market share within two years of launch if trials confirm equivalence and safety.
Key Market Trends
- Regulatory Environment: The FDA approves biosimilars via abbreviated pathways, reducing development costs and time, facilitating earlier market entry.
- Reimbursement Policies: CMS and private insurers increasingly favor biosimilars, pushing prices downward.
- Physician Adoption: Education and trust in biosimilars improve, increasing utilization rates.
- Patent Scenarios: Patent challenges on the originator could accelerate biosimilar market penetration.
Conclusion
NDC 69918-0515 will likely enter the market at a significantly reduced price compared to the originator, with initial pricing roughly 25% lower. Market forces, regulatory environment, and competitive landscape suggest further price reductions over five years, reaching around $100,000 per year. Adoption rates will depend on payer policies, physician confidence, and the success of marketing strategies.
Key Takeaways
- The biosimilar corresponding to NDC 69918-0515 aims for a launch price around 25% less than the originator.
- Price erosion of 5-10% annually is plausible, with prices stabilizing around $100,000 in five years.
- Market share could reach 40% within two years, contingent on regulatory approval and clinician adoption.
- Competition from other biosimilars and originator strategies will heavily influence pricing and market share.
- Regulatory openness and payer policies favor biosimilar growth, supporting sustained price declines.
FAQs
1. When is NDC 69918-0515 expected to launch commercially?
The product was approved by FDA in 2022, with commercial launch anticipated within 6-12 months after approval, depending on manufacturer distribution plans.
2. How does the price of this biosimilar compare to the originator biologic?
The biosimilar is expected to be priced approximately 20-30% below the originator, translating to initial annual costs around $112,500.
3. What factors will most influence the biosimilar’s market share?
Regulatory approval, clinician trust, payer reimbursement policies, and competitive biosimilar entries are key factors.
4. Will the price of NDC 69918-0515 fall further over time?
Yes, prices are projected to decrease by 5-10% annually over the next five years, driven by increased competition and market dynamics.
5. How does biosimilar substitution influence pricing?
Payer incentives and formulary preferences favor substitution, which can lower net prices and accelerate market penetration.
References
[1] IQVIA. (2022). Global Biosimilar Market Overview.
[2] FDA. (2022). Biosimilar Approval and Regulatory Pathways.
[3] Centers for Medicare & Medicaid Services. (2022). Biosimilar Policy Updates.
[4] EvaluatePharma. (2022). Oncology Biosimilars Market Forecast.
